Genebeyond®  is a research and development company focusing on new drug discovery and development, especially on cancer immunotherapy and tissue regeneration. Our biopharmaceutical platforms include monoclonal antibody discovery and design, biologics processes development and scale-up,  synthetic biology, small molecule discovery, etc.  Genebeyond® also provides technical support in deciphering physiological functions and related diseases, new biomarker and  drug target identification and validation  such as cell surface receptors, enzymes, GPCRs, ion channels, protein complexes, cell-cell interactions, etc.

New drug discovery

  Drug targets and biomarkers

  • CDs
  • Cell surface receptors
  • Antigens
  • Neoantigens
  • Enzymes
  • GPCRs
  • Ion channels


  • Monoclonal antibodies (mAb)
  • Recombinant proteins
  • Cells

  Biocompatible materials

  • Biopolymers
  • Tissue regeneration materials
  •  Drug release and delivery materials

Technology Platforms

  Biopharmaceutical Engineering

  • Molecule design
  • Recombinant protein/antibody expression (E. coli, yeast, mammalian cells)
  • Upstream and downstream process development

  Antibody Engineering

  • Therapeutic monoclonal antibody discovery and design
  • Library construction and screening
  • Antibody affinity maturation
  • Antibody humanization
  • Bispecific antibodies (bsAb)
  • Antibody-drug conjugation (ADC)

    High Throughput Drug Screening (HTS)